Proprietary algorithms use NGS to detect multiple fetal genetic abnormalities from non-invasive samples Dec 08, 2015, 08:00 ET from Maverix…
Dr. Stefan Gruenwald
Dr. Gruenwald is the president and co-founder of Diagnomics. Dr. Gruenwald’s career in life science spans more than two decades. He received his MD/PhD at the Johann-Wolfgang Goethe University in Frankfurt, Germany. He later completed his post-doctoral training at the Scripps Research Institute and the University of California San Diego (UCSD).
In 1991, Dr. Gruenwald joined the newly formed PharMingen (now a part of BD Bioscience), which has become one of the most successful San Diego-based biotech companies. At PharMingen, Dr. Gruenwald established and maintained a research team of 155 scientists. His R&D lab cloned over 1,300 genes and expressed more than 200 proteins using various protein expression systems. Dr. Gruenwald holds three patents, based on technologies developed at PharMingen. Dr. Gruenwald is also very experienced in M&A within the life sciences arena. In 1997, he was instrumental in the $75M sale of PharMingen to Fortune 100 Company, Becton Dickinson. He is fluent in English and German.